BACKGROUND

Liver cirrhosis (LC) affect millions of people worldwide. The pathogenesis of cirrhosis involves complex interactions between immune responses and gut microbiota. Recent studies have highlighted the role of the interleukin-36 (IL-36) subfamily in inflammation and immune regulation. However, the relationship between serum IL-36 subfamily levels and gut microbiota in cirrhosis patients remains unclear. This study aimed to explore the clinical significance of serum IL-36 subfamily levels and their association with gut microbiota in cirrhosis patients.

AIM

To explore the clinical significance of serum IL-36 subfamily levels and their relationship with gut microbiota among cirrhosis patients.

METHODS

Sixty-one cirrhosis patients were enrolled from Lihuili Hospital of Ningbo University from May 2022 to November 2023 as the LC group and 29 healthy volunteers as the healthy control (HC) group. The serum expressions of IL-36α, IL-36β, IL-36γ, IL-36Ra, and IL-38 were measured through ELISA, while 16S rRNA gene sequencing was employed to rate microbial community in human fecal samples.

RESULTS

The serum levels of IL-36α, IL-36γ, IL-36Ra, and IL-38 in the LC group remarkably exceeded those in the HC group ( < 0.05). IL-36α, IL-36γ, and IL-38 were related positively to the Child-Pugh score ( < 0.05) and prominently exceeded those in the Child-Pugh C group ( < 0.05). The absolute abundance of harmful bacteria (, , ) remarkably rose, while the beneficial bacteria (, , ) notably decreased in the LC group ( < 0.05). IL-36α, IL-36γ, and IL-38 related positively to ( < 0.05), while IL-38 negatively related to ( < 0.05).

CONCLUSION

IL-36γ and IL-38 show promise as potential biomarkers for LC progression, but further validation is required.